Abstract CT140: NUC-3373, a targeted inhibitor of thymidylate synthase, in patients with advanced colorectal cancer
Farasat Kazmi(University of Oxford), TR Jeffry Evans(Beatson West of Scotland Cancer Centre), Michelle Myers(Nucana (United Kingdom)), Andrew L. Coveler(University of Washington), David J. Harrison(NHS Lothian), Sarah P. Blagden(Churchill Hospital), Jordan Berlin(Dana-Farber Cancer Institute), Janet Graham(Beatson West of Scotland Cancer Centre), Kristen K. Ciombor(The Ohio State University)
Cited by 2
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
High-frequency developmental abnormalities in p53-deficient mice
|Current Biology|1995|467